PTX
US FDA Grants Orphan Drug Designation
to PTX-100 for broader TCL indications
Key points
US FDA grants PTX-100 additional Orphan Drug Designation (ODD) for all T cell
lymphomas
ODD granted for a broader indication than requested by PTX
Confers several developmental benefits and 7 years of market exclusivity
Trial update due shortly
- Forums
- ASX - Day Trading
- Afternoon trading March 8
Afternoon trading March 8, page-120
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online